|Articles|September 19, 2016
ERT eCOA Solution Assists in Migraine Study
ERT has announced that its electronic Clinical Outcome Assessment (eCOA) solution has assisted CoLucid Pharmaceuticals during its Phase III migraine drug study.
Advertisement
ERT has announced that its electronic Clinical Outcome Assessment (eCOA) solution has assisted CoLucid Pharmaceuticals during its Phase III migraine drug study. Patients used the solution to record migraine occurrence and rate headache pain severity as well as other symptoms.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Finalizes Guidance on Clinical Trial Design for Psychedelic Drug Development
2
ACT Brief: Organizational Barriers to Programmatic Recruitment, Scaling Selective Safety Data Collection, and Subcutaneous Alzheimer's Treatment
3
ACT Brief: Portfolio-Level Recruitment Strategy, Real-Time Burden Sampling, and Platinum-Free Bladder Cancer Therapy
4
Selective Safety Data Collection and the Case for Simpler Trials: Q&A with Rob DiCicco, TransCelerate Biopharma
5